undamentalytics Newsletter
Sign in

Roivant Sciences Ltd. revenue

Roivant Sciences Ltd.'s revenue was $8.3m in fiscal 2026, down 71.6% on the year before. Since fiscal 2021 ($23.8m) it has grown at a compound -19.1% a year. Over the last twelve months it was $7.5m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Mar 20212022Mar 20222023Mar 20232024Mar 20242025Mar 20252026Mar 2026LTMJun 2026
Revenue245532332988
Growth on the year before—+132.3%−43.0%+3.8%−11.2%−71.6%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Roivant Sciences Ltd. $7.5m -67.6% -46.4%
Evaxion A/s $7.5m 125.1% —
Adagene Inc. $7.7m 7332.8% —
Tscan Therapeutics, Inc. $7.1m 2.2% -24.3%
Coya Therapeutics, Inc. $8.0m 1793.8% —
Aclaris Therapeutics, Inc. $8.2m -51.0% -35.9%

Compare with peers

Head to head: EVAX vs ROIVADAG vs ROIVROIV vs TCRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Roivant Sciences Ltd.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Roivant Sciences Ltd.